Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.
British regulators fined U.S. drugmaker Pfizer and distributor Flynn Pharma a record $112.7 million Wednesday for increasing the cost of an epilepsy drug by as much as 2,600%.
Pfizer has to give the Texas Health and Human Services Commission drug price information as part of the state's Medicaid program. But that information isn't supposed to be handed over to legislators.
Drugmaker Pfizer says it's reducing what it charges humanitarian groups for its blockbuster vaccine against pneumonia, ear and blood infections.
Doctors Without Borders is refusing 1 million free pneumonia vaccines from Pfizer because it objects to restrictions that often come with donated vaccines. The not-for-profit is also concerned about how Pfizer and other drugmakers use donations to justify charging high prices to other buyers.
There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.
Rising sales of Pfizer's key new medicines and prospects that more drugs will be approved soon have analysts speculating the biggest U.S. drugmaker won't break up after all. Its adjusted earnings amounted to 64 cents per share, two cents better than analysts estimated.
Early last month, U.S. Reps. Diane Black (R-Tenn.) and Earl Blumenauer (D-Ore.)—both of whom sit on the House Ways and Means Committee's Health Subcommittee—introduced a bill that would change how the federal tax code treats high-deductible health plans that are paired with tax-exempt...
Physicians are increasingly selling their practices to larger groups to gain access to the capital and expertise needed to survive under value-based reimbursement.
A federal mandate to use unique device identifiers offers an opportunity to reduce the risk of patients being harmed by products, but the UDI system, which is being implemented over the next four years by the Food and Drug Administration, means a lot of changes— especially for the...
Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.
The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.